About Verve Therapeutics, Inc. - Common Stock (VERV)
Verve Therapeutics is a biotechnology company focused on developing innovative gene-editing therapies aimed at preventing and treating cardiovascular diseases. The company utilizes its proprietary gene-editing technology to precisely target and modify genes associated with high cholesterol and other risk factors for heart disease. By doing so, Verve aims to provide a one-time treatment solution that can significantly reduce the need for lifelong medication and improve long-term health outcomes. With a commitment to transforming the prevention of cardiovascular diseases, Verve Therapeutics is at the forefront of advancing genetic medicine in this critical area of healthcare. Read More
BALA CYNWYD, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verve Therapeutics, Inc. (NASDAQ: VERV) to Eli Lilly and Company is fair to Verve shareholders. Under the terms of the proposed transaction, Verve shareholders will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling the holder to receive up to an additional $3.00 per share upon the achievement of certain milestones.
Power Metallic Mines Inc. (TSXV: PNPN, OTCQB: PNPNF ) has reached a historic milestone by securing the largest exploration license in Saudi Arabia’s Jabal Sayid Belt , marking a major step in the company’s global expansion strategy. The awarded Jabal Baudan project spans over 200 square kilometers , targeting copper, gold, and zinc in one of the Kingdom’s most mineral-rich regions.
Lilly will acquire all outstanding shares of Verve for $10.50 per share in cash payable at closing, in addition to a contingent value right (CVR) per share that entitles holders to $3 per share, subject to the completion of certain milestones.
The Ademi Firm is investigating Verve (Nasdaq: VERV) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly.
BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on May 30, 2025, the company granted equity awards to four new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
BOSTON , May 28, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that management will participate in fireside chats during the following investor conferences:
BOSTON , May 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on April 30, 2025, the company granted equity awards to seven new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
